Automating Biologics Prior Auth in Connecticut

For health systems navigating the complexities of specialty drug approvals, Klivira automates biologics prior auth in Connecticut, ensuring efficient patient access and revenue cycle integrity.

The landscape of biologics prior authorization presents unique challenges for providers in Connecticut, marked by diverse payer requirements and the high-cost nature of these specialty medications. Manual processes for TNF inhibitors, IL-17/IL-23 inhibitors, and other biologics often lead to delays, administrative burden, and potential revenue leakage. Klivira provides a robust solution tailored to this environment.

Navigating Biologics Prior Auth Challenges in Connecticut

Prior authorization for biologics, including high-volume drug classes like TNF inhibitors, IL-17/23, IL-6, and JAK inhibitors, represents a significant administrative burden. In Connecticut, this workflow is further shaped by state-specific Medicaid managed care organizations and a varied commercial payer footprint. Providers must contend with indication-specific criteria, step therapy requirements, and periodic re-authorization cycles that vary across payers and benefit types.

Klivira's Automated Biologics PA Workflow for Connecticut Providers

**Indication Classification:** Identifies the specialty and disease state from EMR diagnoses, ensuring accurate PA criteria application.
**Step Therapy Automation:** Pulls prior-line therapy history (e.g., csDMARDs for rheumatology) from FHIR data to fulfill step therapy requirements.
**Biosimilar Substitution Routing:** Applies per-payer biosimilar mandates, guiding appropriate drug selection based on policy.
**Screening Documentation:** Integrates TB (PPD or IGRA), hepatitis B/C, and immunization status from EMR data for submission.
**Periodic Re-authorization:** Manages typical 6/12-month re-authorization cycles with continuous disease-activity and response documentation.
**Medical-vs-Pharmacy Benefit Routing:** Differentiates between medical and pharmacy benefit pathways for the same agent based on administration mode and payer rules.

Adapting to Connecticut's Payer Landscape for Specialty Medications

Klivira's platform is designed to adapt to the varied prior authorization policies prevalent in Connecticut, encompassing both commercial and state Medicaid plans. By centralizing payer-specific criteria, our system streamlines the submission process for biologics, reducing the need for manual policy lookups and ensuring compliance with diverse state-level PA mandates. This capability is critical for managing the high volume of specialty pharmacy PA, as noted by industry benchmarks like the CAQH Index.

Seamless EMR Integration for Biologics Documentation

Efficient prior authorization for biologics relies heavily on comprehensive clinical documentation. Klivira integrates directly with major EMR systems using SMART on FHIR standards, extracting necessary patient data—such as diagnoses, lab results, and medication history—to auto-populate PA requests. This eliminates redundant data entry, improves data accuracy, and supports the submission of complete X12 278 or ePA forms, accelerating the approval process for high-cost biologic therapies.

Strategic Advantage for Revenue Cycle and Patient Access

Automating biologics prior auth in Connecticut translates directly into tangible benefits for revenue cycle management and patient access teams. By minimizing manual touchpoints and accelerating approval times, clinics and hospitals can reduce administrative costs, decrease denial rates, and ensure patients receive timely access to essential biologic treatments. This operational efficiency is paramount for managing complex and costly specialty drug workflows.

Frequently asked questions

How does Klivira handle step therapy requirements for biologics in Connecticut?

Klivira's platform automates the identification and documentation of prior-line therapy history directly from the EMR. For biologics in Connecticut, this ensures that payer-specific step therapy requirements, such as prior use of csDMARDs for rheumatology or 5-ASA for IBD, are met and properly submitted, reducing potential denials.

Can Klivira manage biosimilar substitution policies for Connecticut payers?

Yes, Klivira incorporates per-payer biosimilar substitution policies into its automated workflow. The system identifies and routes requests based on payer mandates regarding which biosimilars must be tried first, helping providers in Connecticut comply with evolving payer requirements and optimize drug selection.

What EMR integration capabilities does Klivira offer for biologics PA documentation in Connecticut?

Klivira integrates with leading EMR systems via SMART on FHIR, allowing for the direct extraction of clinical data relevant to biologics prior authorization. This includes diagnoses, lab results for screening (e.g., TB, hepatitis), and medication history, streamlining the documentation process for Connecticut providers.

How does Klivira support periodic re-authorization for chronic biologic treatments in Connecticut?

For chronic biologic treatments, Klivira automates the management of periodic re-authorization cycles, typically every 6 or 12 months. The system prompts for and facilitates the submission of continuous disease-activity and response documentation, ensuring ongoing compliance with payer requirements for patients in Connecticut.

Does Klivira differentiate between medical and pharmacy benefit for biologics in Connecticut?

Yes, Klivira's workflow accounts for the distinction between medical and pharmacy benefits, which can vary for the same biologic agent depending on its administration mode and the specific payer. This ensures that the prior authorization request is routed correctly within the Connecticut payer ecosystem, preventing delays or misrouted submissions.